Oral Surgery in Patients Taking Direct Oral Anticoagulants (DOACs): A Practical Review of the Literature

Authors

  • Saturnino Marco Lupi Department of Clinical Surgical, Pediatric and Diagnostic Sciences, University of Pavia, Pavia, Italy
  • Mohammad Reza Dermenaki Farahani Department of Clinical Surgical, Pediatric and Diagnostic Sciences, University of Pavia, Pavia, Italy
  • Elisa Di Ronza Department of Clinical Surgical, Pediatric and Diagnostic Sciences, University of Pavia, Pavia, Italy
  • Michael Cerri Private practice, Borgonovo Val Tidone, Italy
  • Arianna Rodriguez y Baena Post-graduated Specialty in Oral Surgery, Department of Dentistry, IRCCS San Raffaele Hospital and Dental School, Vita Salute University, 20123 Milan, Italy
  • Ruggero Rodriguez y Baena Department of Clinical Surgical, Pediatric and Diagnostic Sciences, University of Pavia, Pavia, Italy

DOI:

https://doi.org/10.12974/2311-8695.2019.07.2

Keywords:

DOACs, Coagulation, Surgery, Peri-operative planning.

Abstract

Recently, four new oral anticoagulant – dabigatran etexilate (direct thrombin inhibitor) and rivaroxaban, apixaban and edoxaban (Xa factor direct inhibitor) – have been approved for the prevention of venous thrombosis and cardiovascular events. As the number of patients taking these drugs is increasing, it is important that the dentist is familiar with these new oral anticoagulants, their indications, methods of action and in particular the management of the patients undergoing oral surgery.

This literature review is conducted to highlight the medical uses of these new oral anticoagulants and their pharmacologic properties, the clinical condition of the patient that may influence the choice to discontinue the DOAC and peri-operative management of the patient. Collaboration with the attending physician is crucial. 

References

Poulakos M, Walker JN, Baig U, David T. Edoxaban: A direct oral anticoagulant. Am J Heal Pharm 2017. https://doi.org/10.2146/ajhp150821

Miranda M, Martinez LS, Franco R, Forte V, Barlattani AJ, Bollero P. Differences between warfarin and new oral anticoagulants in dental clinical practice. Oral Implantol (Rome) 2016; 9: 151-6. https://doi:10.11138/orl/2016.9.3.151

Wienen W, Stassen J-M, Priepke H, Ries UJ, Hauel N. Invitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate. Thromb Haemost 2007. https://doi.org/10.1160/TH07-03-0183

Hauel NH, Nar H, Priepke H, Ries U, Stassen JM, Wienen W. Structure-based design of novel potent nonpeptide thrombin inhibitors. J Med Chem 2002. https://doi.org/10.1021/jm0109513

Stangier J, Rathgen K, Stähle H, Gansser D, Roth W. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 2007. https://doi.org/10.1111/j.1365-2125.2007.02899.x

Gross PL, Weitz JI. New anticoagulants for treatment of venous thromboembolism. Arterioscler Thromb Vasc Biol 2008; 28: 380-6. https://doi.org/10.1161/ATVBAHA.108.162677

Stangier J, Clemens A. Pharmacology, Pharmacokinetics, and Pharmacodynamics of Dabigatran Etexilate, an Oral Direct Thrombin Inhibitor. Clin Appl Thromb 2009. https://doi.org/10.1177/1076029609343004

Firriolo FJ, Hupp WS. Beyond warfarin: The new generation of oral anticoagulants and their implications for the management of dental patients. Oral Surg Oral Med Oral Pathol Oral Radiol 2012. https://doi.org/10.1016/j.oooo.2011.10.005

Food and Drug Administration. Approved drug label n.d. http://www.accessdata.fda.gov/drugsatfda_docs/label/2019/2 02439s029lbl.pdf (accessed June 10, 2019).

Hanken H, Gröbe A, Heiland M, Smeets R, Kluwe L, Wikner J, et al. Postoperative bleeding risk for oral surgery under continued rivaroxaban anticoagulant therapy. Clin Oral Investig 2016. https://doi.org/10.1007/s00784-015-1627-9

Eriksson B, Dahl O, Rosencher N, Kurth A. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total …. Lancet 2007.

Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: The RE-MODEL randomized trial. J Thromb Haemost 2007. https://doi.org/10.1111/j.1538-7836.2007.02748.x

Oral Thrombin Inhibitor Dabigatran Etexilate vs North American Enoxaparin Regimen for Prevention of Venous Thromboembolism After Knee Arthroplasty Surgery. J Arthroplasty 2009. https://doi.org/10.1016/j.arth.2008.01.132

Stangier J, Stähle H, Rathgen K, Roth W, Shakeri-Nejad K. Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment. J Clin Pharmacol 2008. https://doi.org/10.1177/0091270008324179

Castellone DD, Van Cott EM. Laboratory monitoring of new anticoagulants. Am J Hematol 2010; 85: 185-7. https://doi.org/10.1002/ajh.21607

Carlsson SC, Mattsson C, Eriksson UG, Sarich TC, Wåhlander K, Eliasson Å, et al. A review of the effects of the oral direct thrombin inhibitor ximelagatran on coagulation assays. Thromb Res 2005. https://doi.org/10.1016/j.thromres.2004.07.001

Stangier J, Stähle H, Rathgen K, Fuhr R. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet 2008. https://doi.org/10.2165/00003088-200847010-00005

Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, Roth W. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos 2008. https://doi.org/10.1124/dmd.107.019083

Mehta RS. Novel oral anticoagulants. Part II: Direct thrombin inhibitors. Expert Rev Hematol 2010. https://doi.org/10.1586/ehm.10.12

Gnoth MJ, Buetehorn U, Muenster U, Schwarz T, Sandmann S. In vitro and In vivo P-Glycoprotein Transport Characteristics of Rivaroxaban. J Pharmacol Exp Ther 2011. https://doi.org/10.1124/jpet.111.180240

Kubitza D, Becka M, Mueck W, Zuehlsdorf M. Rivaroxaban (BAY 59-7939)--an oral, direct Factor Xa inhibitor--has no clinically relevant interaction with naproxen. Br J Clin Pharmacol 2007; 63: 469-76. https://doi.org/10.1111/j.1365-2125.2006.02776.x

Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman M V., Kakkar AK, et al. Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty. N Engl J Med 2008. https://doi.org/10.1056/NEJMoa0800374

Cocero N, Basso M, Grosso S, Carossa S. Direct Oral Anticoagulants and Medical Comorbidities in Patients Needing Dental Extractions: Management of the Risk of Bleeding. J Oral Maxillofac Surg 2019. https://doi.org/10.1016/j.joms.2018.09.024

Gómez-Moreno G, Fernández-Cejas E, Aguilar-Salvatierra A, de Carlos F, Delgado-Ruiz RA, Calvo-Guirado JL. Dental implant surgery in patients in treatment by dabigatran. Clin Oral Implants Res 2018. https://doi.org/10.1111/clr.12785

Gómez-Moreno G, Aguilar-Salvatierra A, Fernández-Cejas E, Delgado-Ruiz RA, Markovic A, Calvo-Guirado JL. Dental implant surgery in patients in treatment with the anticoagulant oral rivaroxaban. Clin Oral Implants Res 2016. https://doi.org/10.1111/clr.12653

Rodriguez y Baena R, Beltrami R, Tagliabo A, Rizzo S, Lupi SM. Differences between panoramic and Cone Beam-CT in the surgical evaluation of lower third molars. J Clin Exp Dent 2017. https://doi.org/10.4317/jced.53234

Van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, et al. Dabigatran etexilate - A novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010. https://doi.org/10.1160/TH09-11-0758

Downloads

Published

08-03-2019

How to Cite

Lupi, S. M., Farahani, M. R. D., Ronza, E. D., Cerri, M., Baena, A. R. y, & Baena, R. R. y. (2019). Oral Surgery in Patients Taking Direct Oral Anticoagulants (DOACs): A Practical Review of the Literature. The Journal of Dentists, 7, 8–16. https://doi.org/10.12974/2311-8695.2019.07.2

Issue

Section

Articles